December 23, 2024
2 min watch
Save
VIDEO: Leukemia fields ‘moving towards’ menin inhibitors as earlier-line therapy
In this video, Daniel DeAngelo, MD, PhD, discusses a study presented at ASH Annual Meeting that examined the KOMET-007 study into the use of menin inhibitors in patients with acute myeloid leukemia.
DeAngelo, chief of the division of leukemia at Dana-Farber Cancer Institute, highlighted the study, which probed the menin inhibitor ziftomenib [Kura Oncology] combined with intensive therapy.
“We wait for longer follow up for these two approaches, but I think the field is moving towards combination therapy and the use of menin inhibitors in earlier lines of therapy,” DeAngelo said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Reference:Zeidan A, et al. Abstract 214. Presented at: ASH Annual Meeting and Exposition; Dec. 7-10, 2024; San Diego.DeAngelo reports numerous ties to industry.
Read more about